View : 159 Download: 70
Selective inhibition of RANK blocks osteoclast maturation and function and prevents bone loss in mice
- Selective inhibition of RANK blocks osteoclast maturation and function and prevents bone loss in mice
- Kim H.; Han K.C.; Ji H.S.; Kyung H.K.; Ji Y.H.; Seung A.L.; Ko C.-Y.; Kim H.-S.; Shin H.-I.; Hwa J.L.; Jeong D.; Kim N.; Choi Y.; Soo Y.L.
- Ewha Authors
- 이수영; 이화정; 김현수
- SCOPUS Author ID
- 이수영; 이화정
- Issue Date
- Journal Title
- Journal of Clinical Investigation
- Journal of Clinical Investigation vol. 119, no. 4, pp. 813 - 825
- SCI; SCIE; SCOPUS
- Document Type
- Regulation of the formation and function of bone-resorbing osteoclasts (OCs) is a key to understanding the pathogenesis of skeletal disorders. Gene-targeting studies have shown that the RANK signaling pathway plays a critical role in OC differentiation and function. Although pharmaceutical blockade of RANK may be a viable strategy for preventing bone destruction, RANK is implicated in multiple biological processes. Recently, a cytoplasmic motif of RANK was identified that may be specifically involved in OC differentiation. Here, we developed a cell-permeable inhibitor termed the RANK receptor inhibitor (RRI), which targets this motif. The RRI peptide blocked RANKL-induced OC formation from murine bone marrow-derived macrophages. Furthermore, RRI inhibited the resorptive function of OCs and induced OC apoptosis. Treatment with the peptide impaired downstream signaling of RANK linked to Vav3, Rac1, and Cdc42 and resulted in disruptions of the actin cytoskeleton in differentiated OCs. In addition, RRI blocked inflammation-induced bone destruction and protected against ovariectomy-induced bone loss in mice. These data may be useful in the development of selective therapeutic agents for the treatment of osteoporosis and other bone diseases.
- Appears in Collections:
- 자연과학대학 > 생명과학전공 > Journal papers
- Files in This Item:
selective inhibition.pdf(7.7 MB)
- RIS (EndNote)
- XLS (Excel)
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.